Peanut (Arachis hypogaea) Allergen Powder-dnfp Manufacturing Including Standardization Of Allergen Potency

Authors

Stephen Tilles, Aimmune Therapeutics, a Nestlé Health Science company
Stephanie Leonard, University of California San Diego, Rady Children's Hospital
Paul T. Jedrzejewski, Medical Affairs, Aimmune Therapeutics, a Nestlé Health Science company, Brisbane, CA, United States.
Yasushi Ogawa, Medical Affairs, Aimmune Therapeutics, a Nestlé Health Science company, Brisbane, CA, United States.
Soheila Maleki, USDA-Agricultural Research Service
Martin D. Chapman, Indoor Biotechnologies, Inc
George Du Toit, Guy's and St Thomas' NHS Foundation Trust, London, United Kingdom.
S. Shahzad Mustafa, Rochester Regional HealthFollow
Brian P. Vickery, Emory University

Department

Allergy and Immunology

Document Type

Conference Proceeding

Publication Title

Journal of Allergy and Clinical Immunology

Conference Name

American Academy of Allergy, Asthma & Immunology Annual Meeting

Conference Date

2023-02-24 - 2023-02-27

First Page

AB171

DOI

10.1016/j.jaci.2022.12.537

Volume

151

Issue

2, Supplement

Publication Date

2-1-2023

Recommended Citation

Tilles, S., Leonard, S., Jedrzejewski, P. T., Ogawa, Y., Maleki, S., Chapman, M. D., Du Toit, G., Mustafa, S. S., & Vickery, B. (2023). Peanut (Arachis hypogaea) Allergen Powder-dnfp Manufacturing Including Standardization Of Allergen Potency. Journal of Allergy and Clinical Immunology, 151 (2, Supplement), AB171. https://doi.org/10.1016/j.jaci.2022.12.537